[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
19. Pijuan L, Vicioso L, Bellosillo B, Ferrer MD, Baró T, Pedro C, Lloreta-Trull J, Munné A, Serrano S: CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection. Am J Surg Pathol; 2005 Oct;29(10):1399-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
  • It has shown efficacy in patients with B-cell non-Hodgkin lymphoma and also in CD20-positive Hodgkin lymphoma.
  • We report a 34-year-old man with a history of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), treated with different chemotherapy regimens, including anthracyclines and Rituximab.
  • After 4 years in complete remission, he developed a CD20-negative T-cell-rich B-cell lymphoma (TCRBCL) presenting as multiple lung lesions.
  • This case shows the difficulties in the diagnosis of CD20-negative lymphomas when the number of tumor cells is low and when they are found in a predominant T-cell context.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / metabolism. Antineoplastic Agents / therapeutic use. Hodgkin Disease / drug therapy. Lung Neoplasms / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Second Primary / pathology. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Immunohistochemistry. In Situ Hybridization. Lasers. Male. Microdissection. Polymerase Chain Reaction. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160485.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


20. Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A, German Hodgkin Study Group: Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol; 2008 Jan 20;26(3):434-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
  • PURPOSE: Lymphocyte-predominant Hodgkin's lymphoma (LPHL) is rare and differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • [MeSH-major] Hodgkin Disease / pathology. Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Humans. Middle Aged. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Jul;5(7):368-9 [18542117.001]
  • (PMID = 18086799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z, Molnár Z: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res; 2008 Dec;14(4):411-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
  • Clinicopathological features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) differ from those of the classical Hodgkin lymphoma (cHL).
  • We analyzed the clinical features, treatment and survival data of 536 Hodgkin lymphoma patients who had been diagnosed and primarily treated in our institutes between 1995 and 2004.
  • Sixteen (3%) of the patients were diagnosed with NLPHL, 93% of them presented with early-stage disease.
  • None of the patients showed extranodal or splenic involvement or bulky disease.
  • Two NLPHL cases transformed to non-Hodgkin's lymphoma.
  • CONCLUSIONS: NLPHL is a rare disease, thus these are limited experiences with its diagnosis and treatment.
  • Since the disease has an excellent outcome, it is very important to prefer less toxic or local therapies to reach long term survival similar to that of the normal population.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Hungary. Immunohistochemistry. Lymphoma / pathology. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Sep 15;86(6):2312-20 [7662978.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):599-606 [3041849.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Hematol Oncol. 2006 Sep;24(3):146-50 [16729353.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Blood. 2008 Jan 1;111(1):109-11 [17938252.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):184-9 [17591565.001]
  • [Cites] Acta Haematol. 1986;76(1):29-32 [3098024.001]
  • [Cites] Orv Hetil. 2002 Mar 31;143(13):651-61 [11975042.001]
  • [Cites] Blood. 1989 Jan;73(1):47-56 [2462943.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Sep 24;65(3):195-202 [12242134.001]
  • [Cites] Blood. 1996 Jul 15;88(2):657-66 [8695813.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1551-7 [15370206.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):128-32 [16330953.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1063-83 [5947336.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):787-804 [17908620.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:266-72 [17124071.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S45-56 [9926237.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):897-914 [17908627.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • (PMID = 18431694.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Stamatoullas A, Picquenot JM, Dumesnil C, Ruminy P, Penther D, Bertrand P, Courel MN, Maisonneuve C, François A, Gaulard P, Tilly H, Bastard C: Conventional cytogenetics of nodular lymphocyte-predominant Hodgkin's lymphoma. Leukemia; 2007 Sep;21(9):2064-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conventional cytogenetics of nodular lymphocyte-predominant Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / genetics. In Situ Hybridization, Fluorescence. Lymphoma, Follicular / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Cytogenetics. Female. Humans. Karyotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495968.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


23. Siddiqui N, Ayub B, Badar F, Zaidi A: Hodgkin's lymphoma in Pakistan: a clinico-epidemiological study of 658 cases at a cancer center in Lahore. Asian Pac J Cancer Prev; 2006 Oct-Dec;7(4):651-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in Pakistan: a clinico-epidemiological study of 658 cases at a cancer center in Lahore.
  • OBJECTIVES: To study the clinico-epidemiological profile of Hodgkin's lymphoma (HL) in Pakistan.
  • Histopathologically, mixed cellularity (MC) constituted 63.8% of cases, followed by nodular sclerosis (NS) 19.9%, lymphocyte predominant (LP) 7.3% and lymphocyte depleted (LD) 1.2%.
  • Early stage (stage I and II) disease was present in 43.9% of patients at presentation, while 56.1% patients presented with advanced stage (stage III and IV).
  • CONCLUSION: The clinico-epidemiological pattern of Hodgkin's lymphoma in Pakistan manifested is similar to that observed in other developing countries, with male predominance, mixed cellularity as the commonest histological type, advanced stage at presentation and absence of bimodal age distribution.
  • [MeSH-major] Hodgkin Disease / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Pakistan / epidemiology. Registries. Retrospective Studies. Seasons. Social Class


2
Advertisement
4. Donaldson SS, Link MP, Weinstein HJ, Rai SN, Brain S, Billett AL, Hurwitz CA, Krasin M, Kun LE, Marcus KC, Tarbell NJ, Young JA, Hudson MM: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol; 2007 Jan 20;25(3):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.
  • PURPOSE: To evaluate outcome and assess complications in children and adolescents with low-risk Hodgkin's disease treated with vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) chemotherapy and low-dose, involved-field radiation therapy (IFRT).
  • PATIENTS AND METHODS: One hundred ten children with low-risk Hodgkin's disease were treated with four cycles of VAMP and 15 Gy IFRT for those who achieved a complete response (CR) or 25.5 Gy for those with a partial response after two cycles of VAMP.
  • Factors contributing to 10-year EFS were: early CR (P = .02), absence of B symptoms (P = .01), lymphocyte predominant histologic subtype (P = .04), and less than three initial sites of disease (P = .02).
  • Pediatric patients with low-risk Hodgkin's disease can be cured with therapy without an alkylating agent, bleomycin, etoposide, or high-dose, extended-field radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Doxorubicin / therapeutic use. Female. Humans. Male. Methotrexate / therapeutic use. Prednisone / therapeutic use. Risk Factors. Survival Analysis. Treatment Outcome. Vinblastine / therapeutic use


25. Nogovà L, Diehl V, Engert A, German Hodgkin Study Group: Nodular lymphocyte-predominant Hodgkin's lymphoma. Curr Hematol Malig Rep; 2006 Mar;1(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant Hodgkin's lymphoma.
  • Lymphocyte-predominant Hodgkin's lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • Treatment of LPHL patients using standard Hodgkin's lymphoma protocols leads to complete remission in more than 95% of patients.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Histiocytes / pathology. Humans. Lymphocytes / pathology. Neoplasm Staging. Patient Selection. Prognosis. Radiotherapy Dosage. Remission Induction. Rituximab. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Histopathology. 1990 Feb;16(2):157-65 [2323737.001]
  • [Cites] Blood. 2004 Jan 1;103(1):188-93 [12881301.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):559-65 [8573534.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):99-106 [3791150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42 [9256483.001]
  • [Cites] Cancer J. 2002 Sep-Oct;8(5):377-83 [12416895.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):684-7 [12972802.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13 [11858975.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2675-81 [15231567.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1903-10 [14738141.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Feb;17(1):47-53 [15714929.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2948-52 [12885814.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • (PMID = 20425333.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 25
  •  go-up   go-down


26. Jones GL, Taylor PR, Windebank KP, Hoye NA, Lucraft H, Wood K, Angus B, Proctor SJ: Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents. Br J Cancer; 2007 Jul 2;97(1):29-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents.
  • The aim was to assess outcome in a population-based cohort of adolescents with Hodgkin's lymphoma (HL) diagnosed in the UK's northern region over a 10-year period.
  • Seven had nodular lymphocyte-predominant HL, 48 classical HL (cHL).
  • Application of the Scottish and Newcastle Lymphoma Group (SNLG) prognostic index meant 21 patients were considered high risk (index >or=0.5).
  • Scottish and Newcastle Lymphoma Group indexing is not valid for patients under 16.
  • Five- and 10-year overall survival was 93 and 86%, respectively; disease-specific survival was 95 and 92%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / therapeutic use. Cohort Studies. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Survival Analysis. Treatment Outcome. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2769-79 [9256118.001]
  • [Cites] Eur J Cancer. 1991;27(5):624-9 [1828974.001]
  • [Cites] QJM. 1998 Feb;91(2):131-9 [9578895.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2058-63 [10070311.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):670-5 [16007600.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2520-6 [16735704.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3736-44 [10577845.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1500-7 [10735898.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):397-403 [10917558.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1591-8 [1714950.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):100-8 [8418221.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2160-6 [7523608.001]
  • [Cites] Eur J Cancer. 1994;30A(7):1045-6 [7946575.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):812-8 [7717448.001]
  • [Cites] Bone Marrow Transplant. 1995 Dec;16(6):777-82 [8750269.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2622-30 [9215833.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):803-12 [11714108.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):795-806 [11937314.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3081-7 [12118021.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3088-94 [12118022.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3765-71 [12228196.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2026-33 [12743158.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1579-85 [15370209.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):949-59 [7042093.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2547-56 [4052932.001]
  • [Cites] J Clin Oncol. 1987 May;5(5):742-9 [3572464.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1845-50 [3058876.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):897-906 [9508171.001]
  • (PMID = 17533403.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Other-IDs] NLM/ PMC2359673
  •  go-up   go-down


27. Van Loo P, Tousseyn T, Vanhentenrijk V, Dierickx D, Malecka A, Vanden Bempt I, Verhoef G, Delabie J, Marynen P, Matthys P, De Wolf-Peeters C: T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica; 2010 Mar;95(3):440-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response.
  • The aggressive T-cell/histiocyte-rich large B-cell lymphoma and the indolent nodular lymphocyte-predominant Hodgkin's lymphoma are both characterized by a paucity of tumor cells embedded in an overwhelming background.
  • DESIGN AND METHODS: We collected 33 cases of T-cell/histiocyte-rich large B-cell lymphoma and 56 cases of nodular lymphocyte-predominant Hodgkin's lymphoma and performed microarray gene expression profiling on ten cases of each lymphoma, to obtain a better understanding of the lymphoma host response.
  • By quantitative reverse transcriptase polymerase chain reaction we verified that these 20 selected cases were representative of the entire population of T-cell/histiocyte-rich large B-cell and nodular lymphocyte-predominant Hodgkin's lymphomas.
  • RESULTS: We observed that the microenvironment in nodular lymphocyte-predominant Hodgkin's lymphoma is molecularly very similar to a lymph node characterized by follicular hyperplasia, while the microenvironment in T-cell/histiocyte-rich large B-cell lymphoma is clearly different.
  • The T-cell/histiocyte-rich large B-cell lymphoma signature is hallmarked by up-regulation of CCL8, interferon-gamma, indoleamine 2,3 dioxygenase, VSIG4 and Toll-like receptors.
  • These features may be responsible for the recruitment and activation of T cells, macrophages and dendritic cells, characterizing the stromal component of this lymphoma, and may point towards innate immunity and a tumor tolerogenic immune response in T-cell/histiocyte-rich large B-cell lymphoma.
  • CONCLUSIONS: The gene expression profile of T-cell/histiocyte-rich large B-cell lymphoma, in comparison with that of nodular lymphocyte-predominant Hodgkin's lymphoma, shows features suggestive of a distinct tolerogenic host immune response that may play a key role in the aggressive behavior of this lymphoma, and that may serve as a potential target for future therapy.
  • [MeSH-major] Histiocytes / immunology. Hodgkin Disease / immunology. Lymphoma, Large B-Cell, Diffuse / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Child. Female. Gene Expression Profiling. Humans. Immunity, Innate. Immunoenzyme Techniques. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Mar 15;97(6):1845-53 [11238128.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1269-77 [11870169.001]
  • [Cites] Histopathology. 2002 Jan;40(1):31-45 [11903596.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:44-51 [12078902.001]
  • [Cites] Histopathology. 2002 Sep;41(3):216-29 [12207783.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1458-66 [12409722.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1861-7 [12414532.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Nat Rev Immunol. 2004 Oct;4(10):762-74 [15459668.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Am J Surg Pathol. 1988 Jun;12(6):433-43 [3287959.001]
  • [Cites] FASEB J. 1991 Aug;5(11):2516-22 [1907934.001]
  • [Cites] Histopathology. 1991 Sep;19(3):211-20 [1655614.001]
  • [Cites] Am J Surg Pathol. 1992 Jan;16(1):37-48 [1728195.001]
  • [Cites] J Immunol. 1994 Jun 1;152(11):5495-502 [8189067.001]
  • [Cites] J Biol Chem. 1996 Jul 19;271(29):17247-52 [8663541.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42 [9256483.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2679-87 [10194448.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Cell. 2006 Mar 10;124(5):915-27 [16530040.001]
  • [Cites] Oncologist. 2006 Apr;11(4):384-92 [16614234.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):613-25 [16862192.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2817-26 [17016562.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1605-12 [17145596.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1147-54 [17476344.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2871-7 [17164341.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1252-7 [18594468.001]
  • [Cites] J Exp Med. 2008 Sep 29;205(10):2251-68 [18794340.001]
  • [Cites] Cytokine Growth Factor Rev. 2009 Apr;20(2):97-113 [19268625.001]
  • [CommentIn] Haematologica. 2010 Mar;95(3):352-6 [20207840.001]
  • (PMID = 19797726.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2833074
  •  go-up   go-down






Advertisement